4.6 Article

Novel Keto-phospholipids Are Generated by Monocytes and Macrophages, Detected in Cystic Fibrosis, and Activate Peroxisome Proliferator-activated Receptor-γ

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 287, 期 50, 页码 41651-41666

出版社

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M112.405407

关键词

-

资金

  1. National Institutes of Health [HL068878, HL89544, R01-HL058115, R01-HL64937, P30-DK072506, P01-HL103455, R01-AT006822-01]
  2. Wellcome Trust
  3. European Union Marie Curie fellowship
  4. American Heart Association Grant [10SDG4150085]
  5. American Diabetes Association
  6. Academy of Finland
  7. Sigrid Juselius Foundation
  8. American Diabetes Association Junior Faculty Award [7-08-JF 52]
  9. Complexa, Inc.
  10. Nitromega, Inc.

向作者/读者索取更多资源

12/15-Lipoxygenases (LOXs) in monocytes and macrophages generate novel phospholipid-esterified eicosanoids. Here, we report the generation of two additional families of related lipids comprising 15-ketoeicosatetraenoic acid (KETE) attached to four phosphatidylethanolamines (PEs). The lipids are generated basally by 15-LOX in IL-4-stimulated monocytes, are elevated on calcium mobilization, and are detected at increased levels in bronchoalveolar lavage fluid from cystic fibrosis patients (3.6 ng/ml of lavage). Murine peritoneal macrophages generate 12-KETE-PEs, which are absent in 12/15-LOX-deficient mice. Inhibition of 15-prostaglandin dehydrogenase prevents their formation from exogenous 15-hydroxyeicosatetraenoic acid-PE in human monocytes. Both human and murine cells also generated analogous hydroperoxyeicosatetraenoic acid-PEs. The electrophilic reactivity of KETE-PEs is shown by their Michael addition to glutathione and cysteine. Lastly, both 15-hydroxyeicosatetraenoic acid-PE and 15-KETE-PE activated peroxisome proliferator-activated receptor-gamma reporter activity in macrophages in a dose-dependent manner. In summary, we demonstrate novel peroxisome proliferator-activated receptor-gamma-activating oxidized phospholipids generated enzymatically by LOX and 15-prostaglandin dehydrogenase in primary monocytic cells and in a human Th2-related lung disease. The lipids are a new family of bioactive mediators from the 12/15-LOX pathway that may contribute to its known anti-inflammatory actions in vivo.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer

Sarang S. Talwelkar, Mikko I. Mayranpaa, Julia Schuler, Nora Linnavirta, Annabrita Hemmes, Simone Adinolfi, Matti Kankainen, Wolfgang Sommergruber, Anna-Liisa Levonen, Jari Rasanen, Aija Knuuttila, Emmy W. Verschuren, Krister Wennerberg

Summary: Treatment with ALK inhibitors improves outcome for NSCLC patients with ALK-rearranged tumors, but resistance typically develops. In this study, tumor cell cultures were generated from an ALK-rearranged tumor specimen and drug screens identified a role for PI3K beta and EGFR inhibition in enhancing ALK-inhibitor response and preventing resistance. Combinatorial treatment with ALK and PI3K beta inhibitors showed promise in targeting ALK-rearranged NSCLC.

MOLECULAR ONCOLOGY (2023)

Article Microbiology

Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates

Luca A. Robinson, Alice C. Z. Collins, Ronan A. Murphy, Jane C. Davies, Luke P. Allsopp

Summary: This study conducted a comprehensive bioinformatic analysis of 52 high-quality clinical P. aeruginosa genomes isolated from CF patients. The results showed that the clinical CF isolate genome consists mainly of accessory and unique genes, which may provide strain-specific advantages. The study found genetic variability in some effector/immunity encoding genes and identified the presence of orphan vgrG islands in some isolates. The study also revealed disruption to T6SS genomic loci through transposon, prophage, and mobile genetic element insertions.

FRONTIERS IN MICROBIOLOGY (2023)

Editorial Material Immunology

Breathing easy: Dopamine quenches the ILC2 flame

Franz Puttur, Clare M. Lloyd

Summary: In this study, Cao et al. uncover the crucial role of dopamine in inhibiting ILC2 function via metabolic restriction, leading to the improvement of key features in asthma pathogenesis.

IMMUNITY (2023)

Review Immunology

T helper 2 cells in asthma

James A. Harker, Clare M. Lloyd

Summary: Harker and Lloyd review the multifaceted roles of Th2 cells in human asthma, emphasizing the influence of tissue location and disease severity. They also discuss the use of biologic therapies targeting Th2 cells and their cytokines. This review highlights the complex functions of Th2 cells in asthma and how they are affected by tissue location, disease stage, and severity, while also exploring the impact of biologics on asthma and the potential for uncovering new roles for Th2 cells in lung inflammation.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Article Multidisciplinary Sciences

Future therapies for cystic fibrosis

Lucy Allen, Lorna Allen, Siobhan B. Carr, Gwyneth Davies, Damian Downey, Marie Egan, Julian T. Forton, Robert Gray, Charles Haworth, Alexander Horsley, Alan R. Smyth, Kevin W. Southern, Jane C. Davies

Summary: With the introduction of small molecule, mutation-specific drugs, people with cystic fibrosis are undergoing transformative change as these drugs can restore function of the defective protein CFTR. However, not all genetic variants are suitable for mutation-specific drugs and these drugs also do not correct all the clinical manifestations of the disease. More research is needed to improve treatments for cystic fibrosis.

NATURE COMMUNICATIONS (2023)

Article Biochemistry & Molecular Biology

A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies

Jouni Harkonen, Petri Polonen, Ashik Jawahar Deen, Ilakya Selvarajan, Hanna-Riikka Teppo, Elitsa Y. Dimova, Thomas Kietzmann, Maarit Ahtiainen, Juha P. Vayrynen, Sara A. Vayrynen, Hanna Elomaa, Niko Tynkkynen, Tiia Eklund, Teijo Kuopio, Eva-Maria Talvitie, Pekka Taimen, Markku Kallajoki, Minna U. Kaikkonen, Merja Heinaniemi, Anna-Liisa Levonen

Summary: The NRF2 pathway is frequently activated in various cancer types, but a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and conducted a pan-cancer analysis of oncogenic NRF2 signaling using it. Our findings revealed an immunoevasive phenotype in squamous malignancies of the lung, head and neck area, cervix, and esophagus, where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression, and T cell and macrophage infiltration. These tumors have a molecular phenotype with amplification of SOX2/TP63, TP53 mutation, and CDKN2A loss, and are associated with upregulation of immunomodulatory genes NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1, and PD-L1. Our functional genomics analyses suggest that these genes are candidate NRF2 targets, indicating a direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands and increased expression of immunosuppressive ligands NAMPT, SPP1, and WNT5A involved in intercellular crosstalk. Moreover, the negative relationship between NRF2 and immune cells is explained by stromal populations of lung squamous cell carcinoma, indicating a potential effect across multiple squamous malignancies based on our molecular subtyping and deconvolution data.

REDOX BIOLOGY (2023)

Article Infectious Diseases

Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection

Isaac Martin, Sandra Morales, Eric W. F. W. Alton, Jane C. Davies

Summary: This study found that bacteriophages can be used as adjuncts to treatment for antibiotic refractory infections, and the combination of phages with certain antibiotics may have synergistic effects. Furthermore, phages showed good bactericidal effects against antibiotic resistant Pseudomonas aeruginosa (Pa), which may be relevant to ongoing clinical trials.

ANTIBIOTICS-BASEL (2023)

Article Cell Biology

A conversation on allergy: recognizing the past and looking to the future

Erik Melen, Bart N. Lambrecht, Clare M. Lloyd, Marc E. Rothenberg, Kenji Kabashima, Fabio Luciani, Jonathan M. Coquet, Carole Ober, Martijn C. Nawijn, Thomas Platts-Mills, Erika von Mutius

Summary: Allergy is a group of disorders, affecting over 1 billion people worldwide, which includes asthma, atopic dermatitis, rhinitis, and food allergies. Its incidence has dramatically increased since the start of the 20th century, indicating that both genetics and environmental factors play important roles in its development.

IMMUNOLOGY AND CELL BIOLOGY (2023)

Review Immunology

Early-life respiratory infections and developmental immunity determine lifelong lung health

Clare M. M. Lloyd, Sejal Saglani

Summary: Lloyd and Saglani provide an overview of the immunology of respiratory infections in early life and how it impacts lifelong lung health. Respiratory infections are common in infants and young children, and their effects during this developmental stage can have long-term consequences. The immune system and microbiome in the respiratory tract develop simultaneously, and any disruption to this development can have implications for lung health throughout one's life. The authors emphasize the importance of understanding the molecular mechanisms underlying the interplay between immune and structural cells in the lung and the local microorganisms to mitigate harmful effects and restore lung immune health.

NATURE IMMUNOLOGY (2023)

Article Multidisciplinary Sciences

Lung extracellular matrix modulates KRT5+ basal cell activity in pulmonary fibrosis

Richard J. Hewitt, Franz Puttur, David C. A. Gaboriau, Frederic Fercoq, Maryline Fresquet, William J. Traves, Laura L. Yates, Simone A. Walker, Philip L. Molyneaux, Samuel V. Kemp, Andrew G. Nicholson, Alexandra Rice, Edward Roberts, Rachel Lennon, Leo M. Carlin, Adam J. Byrne, Toby M. Maher, Clare M. Lloyd

Summary: This study reveals the impact of changes in extracellular matrix (ECM) composition secreted by lung fibroblasts on the migration and function of KRT5(+) cells in idiopathic pulmonary fibrosis (IPF), contributing to tissue remodeling in the fibrotic lung.

NATURE COMMUNICATIONS (2023)

Article Critical Care Medicine

Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective

Nicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, Scott H. Donaldson, Isabelle Fajac, Christopher H. Goss, Deepika Polineni, Felix Ratjen, Bradley S. Quon, Edith Zemanick, Scott C. Bell, Jane C. Davies, Manu Jain, Michael W. Konstan, Natanya R. Kerper, Tre LaRosa, Marcus A. Mall, Edward McKone, Kelsie Pearson, Joseph M. Pilewski, Lynne Quittell, Jonathan H. Rayment, Steven M. Rowe, Jennifer L. Taylor-Cousar, George Retsch-Bogart, Damian Downey

Summary: The use of modulator therapies for cystic fibrosis has changed clinical trial strategies, dividing the patient population based on eligibility. The development of nucleic acid-based therapies faces challenges due to limited resources and the inability to conduct placebo-controlled trials. Advancing symptomatic therapies is also difficult in a population already receiving modulator treatment.

LANCET RESPIRATORY MEDICINE (2023)

Article Biochemistry & Molecular Biology

The KEAP1-NRF2 pathway: Targets for therapy and role in cancer

Simone Adinolfi, Tommi Patinen, Ashik Jawahar Deen, Sini Pitkänen, Jouni Härkönen, Emilia Kansanen, Jenni Küblbeck, Anna-Liisa Levonen

Summary: The KEAP1-NRF2 pathway is a crucial regulator of cellular defense against oxidative and electrophilic stimuli, playing a significant role in various disease pathologies. Research focused on understanding NRF2 signaling and its downstream effects has led to the identification of novel therapeutic targets. This graphical review provides an updated overview of the KEAP1-NRF2 signaling, highlighting recent advancements in the field, including the mechanism of NRF2 activation and its potential application in cancer diagnostics and treatment.

REDOX BIOLOGY (2023)

Article Respiratory System

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting

Paul McNally, Barry Linnane, Michael Williamson, Basil Elnazir, Christopher Short, Clare Saunders, Laura Kirwan, Rea David, Mariette P. C. van de Corput, Harm A. W. M. Tiddens, Jane C. Davies, Des W. Cox

Summary: In this real-world study, the use of LUM/IVA in children aged 6-11 with CF resulted in improvements in air trapping on CT but worsening in bronchiectasis scores, suggesting that LUM/IVA treatment can improve respiratory function but cannot prevent the progression of bronchiectasis.

RESPIRATORY RESEARCH (2023)

Article Biochemistry & Molecular Biology

Fatty acid nitroalkenes - Multi-target agents for the treatment of sickle cell disease

Fabliha A. Chowdhury, Nicole Colussi, Malini Sharma, Katherine C. Wood, Julia Z. Xu, Bruce A. Freeman, Francisco J. Schopfer, Adam C. Straub

Summary: Sickle cell disease (SCD) is a hereditary hematological disease with high morbidity and mortality rates worldwide. This article evaluates the potential of small molecule nitroalkenes as a therapy for SCD and highlights their protective effects against end organ damage.

REDOX BIOLOGY (2023)

暂无数据